Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
Year wrapped: Tryptamine Therapeutics 2024 milestones, clinical breakthroughs & 2025 vision
MP3•Episod hem
Manage episode 456467223 series 2891889
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll talked with Proactive’s Tylah Tully about the company's remarkable achievements in 2024 and its ambitious plans for 2025. Carroll provided updates on groundbreaking studies involving psilocybin therapies for binge eating disorder, fibromyalgia and irritable bowel syndrome (IBS). Highlighting this year's milestones, Carroll shared that psilocybin therapies demonstrated remarkable efficacy, including a 100% response rate in reducing binge eating episodes and fibromyalgia pain severity. The company also advanced its IV-infused psilocybin formulation, offering consistent and controlled dosing, which addresses limitations of oral treatments. Looking ahead, Carroll outlined three strategic goals for 2025: enhancing intellectual property protections, advancing phase two clinical programs, and developing a commercial-grade formulation for phase three trials. These efforts reflect Tryptamine's dedication to pushing the boundaries of psychedelic-based therapeutics. #ProactiveInvestors #TryptamineTherapeutics #ASX #OTC #ASXTYP #PsilocybinTherapies #MentalHealthInnovation #FibromyalgiaTreatment #IBSResearch #BingeEatingDisorder #ProactiveInterviews #PsychedelicMedicine #HealthcareResearch
…
continue reading
607 episoder
MP3•Episod hem
Manage episode 456467223 series 2891889
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll talked with Proactive’s Tylah Tully about the company's remarkable achievements in 2024 and its ambitious plans for 2025. Carroll provided updates on groundbreaking studies involving psilocybin therapies for binge eating disorder, fibromyalgia and irritable bowel syndrome (IBS). Highlighting this year's milestones, Carroll shared that psilocybin therapies demonstrated remarkable efficacy, including a 100% response rate in reducing binge eating episodes and fibromyalgia pain severity. The company also advanced its IV-infused psilocybin formulation, offering consistent and controlled dosing, which addresses limitations of oral treatments. Looking ahead, Carroll outlined three strategic goals for 2025: enhancing intellectual property protections, advancing phase two clinical programs, and developing a commercial-grade formulation for phase three trials. These efforts reflect Tryptamine's dedication to pushing the boundaries of psychedelic-based therapeutics. #ProactiveInvestors #TryptamineTherapeutics #ASX #OTC #ASXTYP #PsilocybinTherapies #MentalHealthInnovation #FibromyalgiaTreatment #IBSResearch #BingeEatingDisorder #ProactiveInterviews #PsychedelicMedicine #HealthcareResearch
…
continue reading
607 episoder
Kaikki jaksot
×Välkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.